

Herbst, Roy

Institution/Organization

Yale Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

Understood

Disclosure of Potential Conflicts

Understood

COI Disclosure

Disclosures

Immunocore: Interested Person/ Financial; Board Member (non-executive/ independent)

Junshi Pharmaceuticals: Interested Person/ Financial; Board Member (non-executive/ independent)

AstraZeneca: Financial

Bolt Biotherapeutics: Financial

Bristol-Myers Squibb: Financial

Candel Therapeutics, Inc.: Financial

Checkpoint Therapeutics: Financial

DynamiCure Biotechnology, LLC: Financial

eFFECTOR Therapeutics, Inc.: Financial

Eli Lilly and Company: Financial

EMD Serono: Financial

Genentech: Financial

Gilead: Financial

HiberCell, Inc.: Financial

I-Mab Biopharma: Financial

Immune-Onc Therapeutics, Inc.: Financial

Janssen: Financial

Johnson and Johnson: Financial

Loxo Oncology: Financial

Merck and Company: Financial

Mirati Therapeutics: Financial

NextCure: Other Potential Conflict of Interest; Trail Support

Novartis: Financial

Ocean Biomedical, Inc.: Financial

Oncocyte Corp: Financial

Oncternal Therapeutics: Financial

Pfizer: Financial

Regeneron Pharmaceuticals: Financial

Ribbon Therapeutics: Financial

Roche: Financial

Sanofi: Financial

Xencor, Inc: Financial

COI Disclosure Certification

Disclosed

Confidentiality Agreement

Agreed

Standards of Conduct Agreement

Agreed

IASLC's Tax-Exempt Status

Agreed

COI Follow-Up

Disclose any clinical trials you are conducting for institution fees.

A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006), Merck

AZD9291 Versus Placebo in Patients With Stage IB-IIIa Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA), AstraZeneca

A Phase I-2 Trial of NC318 combined with Pembrolizumab in refractory Non-small Cell Lung Cancer: Yale Cancer Center IIT

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

American Association for Cancer Research Society for Immunotherapy of Cancer Southwest Oncology Group

Have you received any personal fees from any outside accreditation entities such as CME companies?

Answers in CME (AICME) Aptitude Health

AXIS Medical Education BioMedical Learning Institute Creative Educational Concepts Clinical Care Options

OncoLive

OE Oncology Education MJH Life Sciences PeerView

PeerVoice

Physicians' Education Resource (PER)

PlatformQ pRIMEOncology Projects In Knowledge Research To Practice RMEI Medical Education Vindico CME

Are you conducting clinical trials with any oncology equipment companies?

No